SkyePharma AG   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Saint-Quentin-Fallavier France (1983)
Status: No NME R&D (1983)

Organization Overview

First Clinical Trial
2004
NCT00830102
First Marketed Drug
1999
isosorbide (isordil)
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Skye Biologics | Skye Biologics, Inc. | Skye Bioscience, Inc. | SKYEPHARMA AG

Active Ingredients

Marketed Drugs (2)

fenofibrate (fenoglide) (2005)

isosorbide (isordil) (1999)

Drugs in Phase 3 Trials (2)

fluticasone (cutivate) (9 trials)

formoterol (foradil) (9 trials)

Drugs in Phase 2 Trials (6)

Key: SkyePharma AG (1) Acquired (5)

ehp-101 (2 trials)

folic acid (1 trial)

gerilimzumab (1 trial)

naltrexone (revia) (1 trial)

nimacimab (1 trial)

sbi-100 (1 trial)

Drugs in Phase 1 Trials (3)

Key: SkyePharma AG (1) Acquired (2)

cannabidiol (Epidiolex) (1 trial)

prednisone (meticorten) (1 trial)

ryi-018 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 11